Abstract
Purpose
Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch’s membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch’s membrane which was successfully treated with intravitreal injection of ranibizumab.
Methods
A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch’s membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch’s membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity.
Results
One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch’s membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed.
Conclusion
For this patient affected with CNV secondary to traumatic Bruch’s membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.
This is a preview of subscription content, log in via an institution to check access.
References
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab(Lucentis). Ophthalmology 114:2179–2182, doi:10.1016/j.ophtha.2007.09.012
Deissler H, Deissler H, Lang S, Lang GE (2008) VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab(Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 92:839–843, doi:10.1136/bjo.2007.135640
Yu HG, Liu X, Kiss S, Connolly E, Gragoudas ES, Michaud NA, Bulgakou OV, Adamian M, Deangelis, Miller JW, Li T, Kim IK (2008) Increased choroidal neovascularization following laser induction in mice lacking lysyl oxidase-like 1. Invest Ophthalmol Vis Sci 49:2599–2605, doi:10.1167/iovs.07-1508
Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosa A, Carvalheira F, Abreu JR, Cunha-Vaz JG (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28:1117–1123, doi:10.1097/IAE.0b013e31817eda41
Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R (2008) Toxoplasmosis Study Group.Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 126:1152–1156, doi:10.1001/archopht.126.8.1152
Narayanan R, Shah VA (2008) Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma. Eur J Ophthalmol 18:466–468
Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL (2008) Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 115:e47–e54, doi:10.1016/j.ophtha.2008.06.021
Chanana B, Azad RV, Kumar N. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture. Eye, 2009 Jan 23. [Epub ahead of print]
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no proprietary interest in the materials used in this study.
Rights and permissions
About this article
Cite this article
Liang, F., Puche, N., Soubrane, G. et al. Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture. Graefes Arch Clin Exp Ophthalmol 247, 1285–1288 (2009). https://doi.org/10.1007/s00417-009-1098-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1098-2